Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Epcoritamab, a bispecific T-cell engager (BiTE) antibody targeting CD3 and CD20, has shown significant efficacy in treating refractory diffuse large B-cell lymphoma (DLBCL). However, its use can lead to severe side effects, such as tumor flare. Here, we report the case of an 84-year-old male with relapsed DLBCL who developed fatal unilateral pleural effusion following Epcoritamab treatment. Initially, the patient showed a favorable response, but later developed significant pleural effusion with elevated interleukin-6 (IL-6) levels, indicating a severe inflammatory response. This suggests that Epcoritamab directly affected the pleural lesions and caused a local cytokine release syndrome (L-CRS). Despite aggressive management, including Tocilizumab and Dexamethasone, the patient's condition worsened, leading to his death. This case underscores the importance of regular lab tests and imaging follow-ups to monitor and manage severe inflammatory reactions based on tumor location. Comprehensive monitoring protocols are needed to mitigate risks associated with novel immunotherapies. To our knowledge, this is the first reported case of fatal unilateral pleural effusion in a patient with relapsed DLBCL following Epcoritamab treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031953 | PMC |
| http://dx.doi.org/10.1007/s00277-025-06206-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pneumonia, a pulmonary abscess, and an empyema caused by Parvimonas micra.
J Infect Dev Ctries
August 2025
Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Background: Pneumonia with an empyema caused by anaerobic bacteria is rare but can be life-threatening, especially in immunocompromised patients.
Case Presentation: A 67-year-old man with diabetes and hypertension who presented with pneumonia and pleural effusion and was unresponsive to initial broad-spectrum antibiotics is presented. Next-generation sequencing identified Parvimonas micra and other pathogens.
Malignant pleural effusion (MPE) is a common complication in advanced cancer, often causing significant dyspnea. We present a case of a 57-year-old woman with recurrent MPE who was managed with intrapleural triamcinolone acetate. The intervention delayed fluid reaccumulation by 15 days and improved her symptoms and functional status, with no adverse effects observed.
View Article and Find Full Text PDFIndex Hepatic Decompensation: Hepatic Hydrothorax Without Signs of Clinically Significant Portal Hypertension Diagnosed With Radioisotope Scintigraphy.
ACG Case Rep J
September 2025
Department of Medicine, University of Arizona College of Medicine, Tucson, AZ.
Hepatic hydrothorax (HH) occurs in 4%-12% of patients with cirrhosis and rarely presents without accompanying evidence of clinically significant portal hypertension (CSPH). We report the case of a 65-year-old man with cirrhosis without prior decompensation, congestive heart failure, and recurrent right-sided pleural effusion. CSPH was not otherwise observed despite thorough laboratory, radiologic, and endoscopic evaluation.
View Article and Find Full Text PDFA Tale of Overlapping Autoimmune Serologies: Diagnosing Hydralazine-Induced Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Related With Isolated Pulmonary Involvement.
Cureus
August 2025
Norton College of Medicine, SUNY Upstate Medical University, Syracuse, USA.
Hydralazine is an antihypertensive that can induce immune-related adverse effects, such as hydralazine-induced lupus and hydralazine-induced antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV involves necrotizing inflammation of small blood vessels, manifesting as fever, malaise, arthralgia, and myalgia, potentially leading to organ failure. Diagnosis includes clinical evaluation, serological testing for ANCA, and histopathological examination, confirmed by necrotizing granulomatous inflammation in affected tissues.
View Article and Find Full Text PDFPostpartum Immune Reconstitution Inflammatory Syndrome Presenting as Massive Bilateral Pleural Effusion in a Previously Healthy Woman: A Case Report.
Cureus
August 2025
Obstetrics and Gynecology, Maa N Baby Hospital, Surat, IND.
Immune reconstitution inflammatory syndrome (IRIS) is commonly described in individuals recovering from immunosuppression, particularly in HIV-positive patients initiating antiretroviral therapy. However, a similar rebound phenomenon can occur postpartum, a period marked by a shift from an immunotolerant to a pro-inflammatory state. IRIS in this context is underrecognized and may present atypically, complicating timely diagnosis.
View Article and Find Full Text PDF